Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Takeda begins enrollment in phase III alogliptin study in China

Feb. 10, 2011

GSK to launch new alli chewable tablet as weight loss aid

Feb. 9, 2011

GSK adds new safety information and restrictions on use to rosiglitazone-containing medicines

Feb. 8, 2011

FDA grants accelerated approval to Hologic's Makena to reduce risk of preterm delivery

Feb. 8, 2011

Lilly and JDRF to study beta-cell regeneration to treat type 1 diabetes

Feb. 7, 2011

Natural marine product largazole has osteogenic potential

Feb. 7, 2011

Partial PPAR-gamma agonist PAM-1616 shows promise in models of diabetes and obesity

Feb. 4, 2011

Temple University divulges new leptin receptor agonists

Feb. 3, 2011

Zymenex's Lamazym advances to phase II in alpha-mannosidosis

Feb. 3, 2011

New GPR119 receptor agonists presented

Feb. 3, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.